Fig. 3From: Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure(Top) The distribution of predicted 5-year risk in type 2 diabetes patients for the composite of heart failure outcome (defined as heart failure hospitalization or CV death) according to the A clinical markers and B clinical and novel biomarkers model. (Bottom) The distribution of individual treatment effect of canagliflozin on the predicted 5-year risk for the composite of heart failure outcome in type 2 diabetes patients in the CANVAS trial according to the C clinical markers and D clinical and novel biomarkers model. Treatment effect is expressed as absolute risk reduction (ARR)Back to article page